Mepolizumab reduces exacerbations in COPD with type 2 inflammation
Adding GSK’s mepolizumab to standard inhaled treatment reduces the frequency of moderate to severe exacerbations in chronic obstructive pulmonary disease (COPD) patients with type 2 inflammation, which contributes to lung inflammation. That’s according to top-line data from a Phase 3 clinical trial called MATINEE (NCT04133909) announced by GSK…